Hepatitis C Market Report 2025

The hepatitis C market size has grown rapidly in recent years. It will grow from $67.17 billion in 2024 to $76.32 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to blood transfusion practices, injection drug use, limited treatment options, development of direct-acting antivirals (DaaS)

The hepatitis C market size is expected to see rapid growth in the next few years. It will grow to $134.03 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to global elimination efforts, improved testing and screening, rising healthcare spending, integration of telemedicine, emerging therapeutic combinations. Major trends in the forecast period include accessible and affordable treatment, focus on high-risk groups, improved drug formulations, collaborative efforts and partnerships, telehealth and digital solutions.

An increase in viral infections is anticipated to drive the growth of the hepatitis C market in the future. Viral infections refer to those caused by viruses in the body. Treatment for hepatitis C helps reduce viral infection by eliminating the virus and restoring the immune response in affected patients after viral clearance. For example, in August 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that the percentage of individuals with Parvovirus B19, a seasonal respiratory viral infection, rose across all age groups, increasing from 3% during 2022-2024 to 10% in June 2024. The most notable rise was among children aged 5-9 years, where prevalence surged from 15% during 2022-2024 to 40% by June 2024. Additionally, the proportion of pooled samples showing parvovirus B19 DNA levels significantly increased from 1.5% in December 2023 to 19.9% in June 2024. Thus, the rise in viral infections is contributing to the growth of the hepatitis C market.

The increasing prevalence of hepatitis is expected to boost the growth of the hepatitis C market in the future. Hepatitis is an inflammatory condition of the liver, often caused by viral infections, particularly hepatitis viruses like A, B, C, D, and E. With a focus on high-risk populations and support from patient advocacy groups, the hepatitis C market continues to progress, providing innovative solutions and advancements in managing this infectious disease. For instance, in April 2024, the CDC reported that the rate of acute hepatitis B among non-Hispanic Black individuals increased by 11.1%, resulting in a rate 1.7 times higher than that of non-Hispanic White individuals during 2021-2022. Therefore, the rising prevalence of hepatitis is driving the hepatitis C market.

A noteworthy trend gaining popularity in the hepatitis C market is the advancement in diagnostic technologies. Major companies in the market are adopting new technologies to maintain their market positions. In July 2022, F. Hoffmann-La Roche Ltd. introduced the Elecsys HCV Duo immunoassay, allowing the independent and simultaneous determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. The test aids in identifying patients recovering from or exhibiting symptoms of chronic infection, potentially leading to other diseases such as liver cancer.

Key players in the hepatitis C market are concentrating on developing advanced products, including dual antigen and antibody diagnostic tests, to enhance the accuracy and efficiency of early detection and treatment. A dual antigen and antibody diagnostic test identifies both the presence of hepatitis C virus (HCV) antigens and antibodies in a patient's blood. For example, in July 2023, Roche Diagnostics, a Switzerland-based company specializing in diagnostic tests, instruments, and digital solutions, launched the Elecsys HCV Duo in India. This dual antigen and antibody diagnostic test is designed for the simultaneous detection of both HCV antigen and antibodies from a single plasma or serum sample. The dual detection feature addresses the challenge posed by asymptomatic early infections, which frequently go undiagnosed due to the lack of antibodies in the initial stages. By enabling the identification of active infections at an earlier stage, the Elecsys HCV Duo assists healthcare providers in initiating appropriate treatment plans more swiftly, potentially mitigating disease progression and reducing transmission rates.

In September 2022, Gilead Sciences Inc. partnered with Brigham and Women's Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center for Health Advancement in Vietnam (HAIVN). This public-private initiative aims to improve the management of viral hepatitis in Vietnam and the Philippines, aligning with the global goal of hepatitis C elimination by 2030. The collaboration involves institutions such as Brigham and Women's Hospital and Beth Israel Deaconess Medical Center in the U.S. and Harvard Medical School.

Major companies operating in the hepatitis C market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffman La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sumitomo Corporation, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Amgen Inc., Toray Industries Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., Biocon Limited.

North America was the largest region in the hepatitis C market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis c market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Hepatitis C is a viral infection that mainly targets the liver, causing inflammation, liver damage, and potentially leading to cirrhosis or liver cancer if left untreated. The virus spreads through contact with infected blood and is treated with antiviral medications designed to eliminate the virus from the bloodstream.

The main types of hepatitis C are chronic hepatitis C, acute hepatitis C, and others. Chronic hepatitis C denotes a persistent infection caused by the hepatitis C virus, occurring when the body is unable to effectively combat the virus. Treatment options for chronic hepatitis C include antiviral drugs, vaccines, immune modulator drugs, surgery, and others. The diagnostic process typically involves liver biopsy, blood tests, imaging tests, and others, with distribution through hospital and retail pharmacies, as well as online pharmacies. End-users encompass hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, research institutes, and home care settings.

The hepatitis C market research report is one of a series of new reports that provides hepatitis C market statistics, including hepatitis C industry global market size, regional shares, competitors with a hepatitis C market share, detailed hepatitis C market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis C industry. This hepatitis C market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis C market consists of revenues earned by entities by providing shunt procedures, hepatic resection, and biopsies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C market also includes sales of ledipasvir and sofosbuvir, non-structural protein 5B (NS5B) polymerase inhibitors, non-structural protein 5A (NS5A) replication complex inhibitors, and elbasvir and grazoprevir drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.